Fulgent Genetics (FLGT) UBS Global Healthcare Conference 2024 summary

Business performance and growth

• Achieved strong Q3 results with all business segments growing and precision diagnostics up 20% sequentially.

• Reiterated 2024 revenue guidance of $280 million and year-end cash balance of at least $800 million.

• Expanded from a niche rare disease focus to a broad menu of 22,000 genetic tests across multiple healthcare areas.

• Growth driven by both organic expansion and acquisitions, including Inform Diagnostics and CSI Laboratories.

• Won a $99 million, five-year hereditary cancer contract with the VA, expanding addressable market.

Market dynamics and competitive positioning

• Gained market share as competitors exited, especially in reproductive and women's health.

• Maintained best-in-class cost structure and operational stability, attracting clients seeking reliability.

• Plans to continue market share gains and operational execution into 2025.

• Sales team expansion is ongoing, with a focus on hiring experienced, specialized reps.

• Anatomic pathology (AP) business returned to growth after headwinds, with robust sales pipeline and improved operations.

Product innovation and portfolio

• Carrier screening is the highest volume test, with most business in large panels for infertility clinics.

• Launched KNOVA, a novel NIPT test with unique de novo point mutation detection, aiming to penetrate OB/GYN market.

• Customizable genetic panels and rapid turnaround times differentiate offerings.

• Expanded carrier screening is standard in infertility clinics, with guidelines expected to evolve.